Division of Medicine, UCL Medical School, London, UK.
J Gene Med. 2012 Feb;14(2):109-19. doi: 10.1002/jgm.1639.
Single-stranded DNA oligonucleotides (ssODNs) can introduce small, specific sequence alterations into genomes. Potential applications include creating disease-associated mutations in cell lines or animals, functional studies of single nucleotide polymorphisms and, ultimately, clinical therapy by correcting genetic point mutations. Here, we report feasibility studies into realizing this potential by targeting a reporter gene, mutated enhanced green fluorescent protein (mEGFP).
Three mammalian cell lines, CHO, HEK293T and HepG2, expressing multiple copies of mEGFP were transfected with a 27-mer ssODN capable of restoring fluorescence. Successful cell correction was quantified by flow cytometry.
Gene editing in each isogenic cell line, as measured by percentage of green cells, correlated tightly with target protein levels, and thus gene expression. In the total population, 2.5% of CHO-mEGFP cells were successfully edited, although, remarkably, in the highest decile producing mEGFP protein, over 20% of the cells had restored green fluorescence. Gene-edited clones initially selected for green fluorescence lost EGFP expression during cell passaging, which partly reflected G2-phase cycle arrest and perhaps eventual cell death. The major cause, however, was epigenetic down-regulation; incubation with sodium butyrate or 5-aza-2'-deoxycytidine reactivated fluorescent EGFP expression and hence established that the repaired genotype was stable.
Our data establish that ssODN-mediated gene editing is underestimated in cultured mammalian cells expressing nonfluorescent mutated EGFP, because of variable expression of this mEGFP target gene in the cell population. This conclusion was endorsed by studies in HEK293T-mEGFP and HepG2-mEGFP cells. We infer that oligonucleotide-directed editing of endogenous genes is feasible, particularly for those that are transcriptionally active.
单链 DNA 寡核苷酸 (ssODN) 可将小的、特定的序列改变引入基因组中。潜在的应用包括在细胞系或动物中创建与疾病相关的突变、对单核苷酸多态性进行功能研究,以及最终通过纠正遗传点突变进行临床治疗。在这里,我们报告了通过靶向报告基因、突变增强型绿色荧光蛋白 (mEGFP) 来实现这一潜力的可行性研究。
用能够恢复荧光的 27 个碱基对的 ssODN 转染表达多个 mEGFP 拷贝的三种哺乳动物细胞系 CHO、HEK293T 和 HepG2。通过流式细胞术定量测定细胞的成功校正。
用绿色细胞百分比衡量的每种同基因细胞系的基因编辑与靶蛋白水平密切相关,因此与基因表达相关。在总群体中,CHO-mEGFP 细胞的成功编辑率为 2.5%,尽管令人惊讶的是,在产生 mEGFP 蛋白的最高十分位数中,超过 20%的细胞恢复了绿色荧光。最初选择绿色荧光的基因编辑克隆在细胞传代过程中失去了 EGFP 表达,这部分反映了 G2 期细胞周期停滞,也许最终导致细胞死亡。然而,主要原因是表观遗传下调;用丁酸钠或 5-氮杂-2'-脱氧胞苷孵育可重新激活荧光 EGFP 表达,从而证实修复的基因型是稳定的。
我们的数据表明,在表达非荧光突变型 EGFP 的培养哺乳动物细胞中,ssODN 介导的基因编辑被低估了,因为该 mEGFP 靶基因在细胞群体中的表达存在差异。这一结论得到了 HEK293T-mEGFP 和 HepG2-mEGFP 细胞研究的支持。我们推断,寡核苷酸指导的内源性基因编辑是可行的,特别是对于那些转录活跃的基因。